Z6尊龙凯时

2026 ESMO | Satricabtagene autoleucel (satri-cel) as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction cancer (G/GEJC): preliminary results from a phase Ib trial

2026 EHA | First-in-Human Study of CT0596, an Allogeneic BCMA CAR T in Relapsed/Refractory Multiple Myeloma and Primary Plasma Cell Leukemia: Safety, Efficacy, and Pharmacokinetic at Recommended Dose

2026 EHA | First in Human Study of CT1190B, an Allogeneic Anti-CD19/CD20 CAR T-cell Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

2026 ASCO | Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a subgroup analysis

2025 ASH | A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics 2025 Investor Day